The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Head and neck squamous cell carcinoma (HNSCC) carries a poor prognosis, with low survival rates for advanced stage tumors and minimal improvement in survival trends through the past decades. It is becoming increasingly clear that HNSCC oncogenesis and evolution is characterized by profound immune defects, as cancer cells evade immunosurveillance due to accumulation of genetic mutations and tumor heterogeneity. Improved understanding of the role of the immune system in cancer has led to the identification of novel therapeutic targets, which are being investigated for their potential to provide durable responses. In this review, we will summarize the role of the immune system in HNSCC, the rationale behind immunotherapy strategies and their clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 2×
“Recruitment of immunosuppressive cells in tumor microenvironment plays a major role in immune escape in HNSCC. MDSCs are immature myeloid populations that are recruited to the tumors after secretion of soluble immunosuppressive factors, such as PGE2, IL-6, GM-CSF, IL-10, VEGF, and TGF-b1 (51).”
BackgroundDecoding the Patterns of Self and Nonself by the Innate Immune System
Medzhitov, R., & Janeway, C. A. (2002) · Science · doi:10.1126/science.1068883 · Cited by 2,154 · cited 1×
“In contrast, adaptive immunity relies upon somatic cell gene rearrangements to produce a multitude of antigen receptors that discriminate between closely related molecules; it is mainly driven by highly specific antigen receptors on T and B cells and is highly specific to a particular pathogen (9).”
BackgroundInhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Cited by
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180
“The use of immunotherapy for HNSC tumors is under active investigation (Economopoulou et al., 2016; Fuer-eder, 2016) with the recent FDA approval of pembrolizumab; however, whether the effectiveness of therapy is limited to spe-cific HNSC molecular subtypes is not clear from those reports.”
BackgroundOral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy
Driehuis, E., Kolders, S., Spelier, S., Lõhmussaar, K., Willems, S. M., Devriese, L. A., de Bree, R., de Ruiter, E. J., Korving, J., Begthel, H., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1522 · Cited by 408
“Such drugs are currently evaluated in patients with HNSCC (71).”
BackgroundGarton, A. J., Seibel, S., Lopresti-Morrow, L., Crew, L., Janson, N., Mandiyan, S., Trombetta, E. S., Pankratz, S., LaVallee, T. M., & Gedrich, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0676 · Cited by 32
Zhao, Z., Li, Y., Wu, Y., & Chen, R. (2019) · Cancer Biomarkers · doi:10.3233/cbm-190380 · Cited by 23
“The present study will provide a new idea for the effective clinical treatment of HNSCC.HNSCC has been regarded as an immune-suppressive disease characterized by profound immune defects [31].”
Metadata
- Authors
- Economopoulou, P., Perisanidis, C., Giotakis, E. I., & Psyrri, A.
- Venue
- Annals of Translational Medicine
- Publisher
- AME Publishing Company
- Published
- 2016-05
- Volume
- 4
- Issue
- 9
- Pages
- 173-173
- ISSN
- 2305-5839 (ISSN-L)
- 2305-5847
- OpenAlex
- W2397540382
- Cited by
- 103
- References
- 4
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.